Skip to main content
Top
Published in: Cancer Causes & Control 10/2012

01-10-2012 | Original paper

The risk of a second primary lung cancer after a first invasive breast cancer according to estrogen receptor status

Authors: Sara J. Schonfeld, Rochelle E. Curtis, William F. Anderson, Amy Berrington de González

Published in: Cancer Causes & Control | Issue 10/2012

Login to get access

Abstract

Purpose

Lung cancers account for 5 % of second primary cancers after breast cancer. The low overall 5-year relative survival rate of lung cancer makes it a particularly concerning new malignancy for breast cancer survivors. It is unknown whether second lung cancer risk varies by estrogen receptor (ER) expression of the first breast cancer.

Methods

We evaluated second primary lung cancer risks using standardized incidence ratios (SIRs) (95 % confidence intervals (CIs)) among 222,148 one-year breast cancer survivors in the NCI-SEER Program registry database (1992–2008). Relative risks (RRs) and 95 % CIs for lung cancer following ER compared with ER+ breast cancer were estimated using Poisson regression, adjusted for age, year, and stage of breast cancer diagnosis, attained age, latency, and radiotherapy. We also examined the reciprocal association of second ER and ER+ breast cancers among 28,107 1-year lung cancer survivors.

Results

There were 418 and 1,444 second lung cancers diagnosed following 50,781 ER and 171,367 ER+ breast cancers. Second lung cancer rates were significantly elevated after ER (SIR = 1.20 (1.09–1.33)), but not ER+ (SIR = 0.96 (0.91–1.01)) breast cancer. The adjusted RR for a second lung cancer following ER compared with ER+ breast cancer was 1.22 (1.10–1.37). The reciprocal adjusted RR for a second ER compared with ER+ breast cancer following lung cancer was 1.29 (0.98–1.70).

Conclusion

The parallel increase for a second lung cancer following an ER first breast cancer and for a second ER breast cancer after a first lung cancer suggests that there may be shared etiologic factors for these cancers. Further evaluation of lung cancer risk after ER breast cancer may identify women at high risk for this fatal malignancy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Howlader NA, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK, eds. SEER Cancer Statistics Review, 1975–2008. National Cancer Institute, http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011, Bethesda, MD Howlader NA, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK, eds. SEER Cancer Statistics Review, 1975–2008. National Cancer Institute, http://​seer.​cancer.​gov/​csr/​1975_​2008/​, based on November 2010 SEER data submission, posted to the SEER web site, 2011, Bethesda, MD
2.
go back to reference Hayat MJ, Howlader N, Reichman ME, Edwards BK (2007) Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 12(1):20–37PubMedCrossRef Hayat MJ, Howlader N, Reichman ME, Edwards BK (2007) Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 12(1):20–37PubMedCrossRef
3.
go back to reference Mariotto AB, Rowland JH, Ries LA, Scoppa S, Feuer EJ (2007) Multiple cancer prevalence: a growing challenge in long-term survivorship. Cancer Epidemiol Biomarkers Prev 16(3):566–571PubMedCrossRef Mariotto AB, Rowland JH, Ries LA, Scoppa S, Feuer EJ (2007) Multiple cancer prevalence: a growing challenge in long-term survivorship. Cancer Epidemiol Biomarkers Prev 16(3):566–571PubMedCrossRef
4.
go back to reference Curtis RE, Ron E, Hankey BF, Hoover RN (2006) New malignancies following breast cancer. In: Curtis RE, Freedman DM, Ron E et al. (eds) New malignancies among cancer survivors: SEER Cancer Registries, 1973–2000. National Cancer Institute. NIH Publ. No. 05-5302, Bethesda, MD, pp 181–205 Curtis RE, Ron E, Hankey BF, Hoover RN (2006) New malignancies following breast cancer. In: Curtis RE, Freedman DM, Ron E et al. (eds) New malignancies among cancer survivors: SEER Cancer Registries, 1973–2000. National Cancer Institute. NIH Publ. No. 05-5302, Bethesda, MD, pp 181–205
5.
go back to reference Roychoudhuri R, Evans H, Robinson D, Moller H (2004) Radiation-induced malignancies following radiotherapy for breast cancer. Br J Cancer 91(5):868–872PubMed Roychoudhuri R, Evans H, Robinson D, Moller H (2004) Radiation-induced malignancies following radiotherapy for breast cancer. Br J Cancer 91(5):868–872PubMed
6.
go back to reference Berrington de Gonzalez A, Curtis RE, Gilbert E, Berg CD, Smith SA, Stovall M, Ron E (2010) Second solid cancers after radiotherapy for breast cancer in SEER cancer registries. Br J Cancer 102(1):220–226PubMedCrossRef Berrington de Gonzalez A, Curtis RE, Gilbert E, Berg CD, Smith SA, Stovall M, Ron E (2010) Second solid cancers after radiotherapy for breast cancer in SEER cancer registries. Br J Cancer 102(1):220–226PubMedCrossRef
7.
go back to reference Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R, Taylor C, Wang Y (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366(9503):2087–2106PubMed Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R, Taylor C, Wang Y (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366(9503):2087–2106PubMed
8.
go back to reference Zablotska LB, Neugut AI (2003) Lung carcinoma after radiation therapy in women treated with lumpectomy or mastectomy for primary breast carcinoma. Cancer 97(6):1404–1411PubMedCrossRef Zablotska LB, Neugut AI (2003) Lung carcinoma after radiation therapy in women treated with lumpectomy or mastectomy for primary breast carcinoma. Cancer 97(6):1404–1411PubMedCrossRef
9.
go back to reference Schaapveld M, Visser O, Louwman MJ, de Vries EG, Willemse PH, Otter R, van der Graaf WT, Coebergh JW, van Leeuwen FE (2008) Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol 26(8):1239–1246PubMedCrossRef Schaapveld M, Visser O, Louwman MJ, de Vries EG, Willemse PH, Otter R, van der Graaf WT, Coebergh JW, van Leeuwen FE (2008) Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol 26(8):1239–1246PubMedCrossRef
10.
go back to reference Lorigan P, Califano R, Faivre-Finn C, Howell A, Thatcher N (2010) Lung cancer after treatment for breast cancer. Lancet Oncol 11(12):1184–1192PubMedCrossRef Lorigan P, Califano R, Faivre-Finn C, Howell A, Thatcher N (2010) Lung cancer after treatment for breast cancer. Lancet Oncol 11(12):1184–1192PubMedCrossRef
11.
go back to reference Anderson WF, Chatterjee N, Ershler WB, Brawley OW (2002) Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 76(1):27–36PubMedCrossRef Anderson WF, Chatterjee N, Ershler WB, Brawley OW (2002) Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 76(1):27–36PubMedCrossRef
12.
go back to reference Curtis RE, Ries LAG (2006) Methods. In: Curtis RE, Freedman DM, Ron E et al. (eds) New malignancies among cancer survivors: SEER cancer registries, 1973–2000. National Cancer Institute. NIH Publ. No. 05-5302, Bethesda, MD, pp 9–14 Curtis RE, Ries LAG (2006) Methods. In: Curtis RE, Freedman DM, Ron E et al. (eds) New malignancies among cancer survivors: SEER cancer registries, 1973–2000. National Cancer Institute. NIH Publ. No. 05-5302, Bethesda, MD, pp 9–14
13.
go back to reference Fritz AG (2000) International classification of diseases for oncology : ICD-O, 3rd edn. World Health Organization, Geneva Fritz AG (2000) International classification of diseases for oncology : ICD-O, 3rd edn. World Health Organization, Geneva
14.
go back to reference Liddell FD (1984) Simple exact analysis of the standardised mortality ratio. J Epidemiol Commun Health 38(1):85–88CrossRef Liddell FD (1984) Simple exact analysis of the standardised mortality ratio. J Epidemiol Commun Health 38(1):85–88CrossRef
16.
go back to reference Yasui Y, Liu Y, Neglia JP, Friedman DL, Bhatia S, Meadows AT, Diller LR, Mertens AC, Whitton J, Robison LL (2003) A methodological issue in the analysis of second-primary cancer incidence in long-term survivors of childhood cancers. Am J Epidemiol 158(11):1108–1113PubMedCrossRef Yasui Y, Liu Y, Neglia JP, Friedman DL, Bhatia S, Meadows AT, Diller LR, Mertens AC, Whitton J, Robison LL (2003) A methodological issue in the analysis of second-primary cancer incidence in long-term survivors of childhood cancers. Am J Epidemiol 158(11):1108–1113PubMedCrossRef
17.
go back to reference Preston D, Lubin J, Pierce D, McConney M (1993) EPICURE user’s guide. HiroSoft International Corporation, Seattle, WA Preston D, Lubin J, Pierce D, McConney M (1993) EPICURE user’s guide. HiroSoft International Corporation, Seattle, WA
18.
go back to reference Akaike H (1973) In: Petrov BN, Csaki F (eds) 2nd International Symposium on Information Theory. Akademiai Kiado, Budapest, pp 267–281 Akaike H (1973) In: Petrov BN, Csaki F (eds) 2nd International Symposium on Information Theory. Akademiai Kiado, Budapest, pp 267–281
19.
20.
go back to reference Mellemkjaer L, Friis S, Olsen JH, Scelo G, Hemminki K, Tracey E, Andersen A, Brewster DH, Pukkala E, McBride ML, Kliewer EV, Tonita JM, Kee-Seng C, Pompe-Kirn V, Martos C, Jonasson JG, Boffetta P, Brennan P (2006) Risk of second cancer among women with breast cancer. Int J Cancer 118(9):2285–2292PubMedCrossRef Mellemkjaer L, Friis S, Olsen JH, Scelo G, Hemminki K, Tracey E, Andersen A, Brewster DH, Pukkala E, McBride ML, Kliewer EV, Tonita JM, Kee-Seng C, Pompe-Kirn V, Martos C, Jonasson JG, Boffetta P, Brennan P (2006) Risk of second cancer among women with breast cancer. Int J Cancer 118(9):2285–2292PubMedCrossRef
21.
go back to reference Brown LM, Chen BE, Pfeiffer RM, Schairer C, Hall P, Storm H, Pukkala E, Langmark F, Kaijser M, Andersson M, Joensuu H, Fossa SD, Travis LB (2007) Risk of second non-hematological malignancies among 376,825 breast cancer survivors. Breast Cancer Res Treat 106(3):439–451PubMedCrossRef Brown LM, Chen BE, Pfeiffer RM, Schairer C, Hall P, Storm H, Pukkala E, Langmark F, Kaijser M, Andersson M, Joensuu H, Fossa SD, Travis LB (2007) Risk of second non-hematological malignancies among 376,825 breast cancer survivors. Breast Cancer Res Treat 106(3):439–451PubMedCrossRef
22.
go back to reference Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM, Milton DT, Strawn JR, Wakelee HA, Giaccone G (2011) American society of clinical oncology provisional clinical opinion: epidermal growth Factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 29(15):2121–2127PubMedCrossRef Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM, Milton DT, Strawn JR, Wakelee HA, Giaccone G (2011) American society of clinical oncology provisional clinical opinion: epidermal growth Factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 29(15):2121–2127PubMedCrossRef
23.
go back to reference de Ruijter TC, Veeck J, de Hoon JP, van Engeland M, Tjan-Heijnen VC (2011) Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol 137(2):183–192PubMedCrossRef de Ruijter TC, Veeck J, de Hoon JP, van Engeland M, Tjan-Heijnen VC (2011) Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol 137(2):183–192PubMedCrossRef
24.
go back to reference Burness ML, Grushko TA, Olopade OI (2010) Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker? Cancer J 16(1):23–32PubMedCrossRef Burness ML, Grushko TA, Olopade OI (2010) Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker? Cancer J 16(1):23–32PubMedCrossRef
25.
go back to reference Khatcheressian JL, Wolff AC, Smith TJ, Grunfeld E, Muss HB, Vogel VG, Halberg F, Somerfield MR, Davidson NE (2006) American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 24(31):5091–5097PubMedCrossRef Khatcheressian JL, Wolff AC, Smith TJ, Grunfeld E, Muss HB, Vogel VG, Halberg F, Somerfield MR, Davidson NE (2006) American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 24(31):5091–5097PubMedCrossRef
26.
go back to reference Tennis M, Singh B, Hjerpe A, Prochazka M, Czene K, Hall P, Shields PG (2010) Pathological confirmation of primary lung cancer following breast cancer. Lung Cancer 69(1):40–45PubMedCrossRef Tennis M, Singh B, Hjerpe A, Prochazka M, Czene K, Hall P, Shields PG (2010) Pathological confirmation of primary lung cancer following breast cancer. Lung Cancer 69(1):40–45PubMedCrossRef
27.
go back to reference Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11(12):1135–1141PubMedCrossRef Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11(12):1135–1141PubMedCrossRef
28.
go back to reference Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast And Bowel Project P-1 Study. J Natl Cancer Inst 90(18):1371–1388PubMedCrossRef Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast And Bowel Project P-1 Study. J Natl Cancer Inst 90(18):1371–1388PubMedCrossRef
29.
go back to reference Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (9472):1687–1717 Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (9472):1687–1717
30.
go back to reference Lorigan P, Radford J, Howell A, Thatcher N (2005) Lung cancer after treatment for Hodgkin’s lymphoma: a systematic review. Lancet Oncol 6(10):773–779PubMedCrossRef Lorigan P, Radford J, Howell A, Thatcher N (2005) Lung cancer after treatment for Hodgkin’s lymphoma: a systematic review. Lancet Oncol 6(10):773–779PubMedCrossRef
31.
go back to reference Malin JL, Kahn KL, Adams J, Kwan L, Laouri M, Ganz PA (2002) Validity of cancer registry data for measuring the quality of breast cancer care. J Natl Cancer Inst 94(11):835–844PubMedCrossRef Malin JL, Kahn KL, Adams J, Kwan L, Laouri M, Ganz PA (2002) Validity of cancer registry data for measuring the quality of breast cancer care. J Natl Cancer Inst 94(11):835–844PubMedCrossRef
32.
go back to reference Alberg AJ, Ford JG, Samet JM (2007) Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132(3 Suppl):29S–55SPubMedCrossRef Alberg AJ, Ford JG, Samet JM (2007) Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132(3 Suppl):29S–55SPubMedCrossRef
33.
go back to reference Johnson KC, Miller AB, Collishaw NE, Palmer JR, Hammond SK, Salmon AG, Cantor KP, Miller MD, Boyd NF, Millar J, Turcotte F (2011) Active smoking and secondhand smoke increase breast cancer risk: the report of the Canadian expert panel on tobacco smoke and breast cancer risk (2009). Tob Control 20(1):e2PubMedCrossRef Johnson KC, Miller AB, Collishaw NE, Palmer JR, Hammond SK, Salmon AG, Cantor KP, Miller MD, Boyd NF, Millar J, Turcotte F (2011) Active smoking and secondhand smoke increase breast cancer risk: the report of the Canadian expert panel on tobacco smoke and breast cancer risk (2009). Tob Control 20(1):e2PubMedCrossRef
34.
go back to reference Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME (2004) Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 13(10):1558–1568PubMed Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME (2004) Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 13(10):1558–1568PubMed
35.
go back to reference Kabat GC, Kim M, Phipps AI, Li CI, Messina CR, Wactawski-Wende J, Kuller L, Simon MS, Yasmeen S, Wassertheil-Smoller S, Rohan TE (2011) Smoking and alcohol consumption in relation to risk of triple-negative breast cancer in a cohort of postmenopausal women. Cancer Causes Control 22(5):775–783PubMedCrossRef Kabat GC, Kim M, Phipps AI, Li CI, Messina CR, Wactawski-Wende J, Kuller L, Simon MS, Yasmeen S, Wassertheil-Smoller S, Rohan TE (2011) Smoking and alcohol consumption in relation to risk of triple-negative breast cancer in a cohort of postmenopausal women. Cancer Causes Control 22(5):775–783PubMedCrossRef
36.
go back to reference Li CI, Malone KE, Daling JR (2005) The relationship between various measures of cigarette smoking and risk of breast cancer among older women 65–79 years of age (United States). Cancer Causes Control 16(8):975–985PubMedCrossRef Li CI, Malone KE, Daling JR (2005) The relationship between various measures of cigarette smoking and risk of breast cancer among older women 65–79 years of age (United States). Cancer Causes Control 16(8):975–985PubMedCrossRef
37.
go back to reference Terry PD, Rohan TE (2002) Cigarette smoking and the risk of breast cancer in women: a review of the literature. Cancer Epidemiol Biomarkers Prev 11(10 Pt 1):953–971PubMed Terry PD, Rohan TE (2002) Cigarette smoking and the risk of breast cancer in women: a review of the literature. Cancer Epidemiol Biomarkers Prev 11(10 Pt 1):953–971PubMed
38.
go back to reference Manjer J, Malina J, Berglund G, Bondeson L, Garne JP, Janzon L (2001) Smoking associated with hormone receptor negative breast cancer. Int J Cancer 91(4):580–584PubMedCrossRef Manjer J, Malina J, Berglund G, Bondeson L, Garne JP, Janzon L (2001) Smoking associated with hormone receptor negative breast cancer. Int J Cancer 91(4):580–584PubMedCrossRef
39.
go back to reference Al-Delaimy WK, Cho E, Chen WY, Colditz G, Willet WC (2004) A prospective study of smoking and risk of breast cancer in young adult women. Cancer Epidemiol Biomarkers Prev 13(3):398–404PubMed Al-Delaimy WK, Cho E, Chen WY, Colditz G, Willet WC (2004) A prospective study of smoking and risk of breast cancer in young adult women. Cancer Epidemiol Biomarkers Prev 13(3):398–404PubMed
40.
go back to reference Xue F, Willett WC, Rosner BA, Hankinson SE, Michels KB (2011) Cigarette smoking and the incidence of breast cancer. Arch Intern Med 171(2):125–133PubMedCrossRef Xue F, Willett WC, Rosner BA, Hankinson SE, Michels KB (2011) Cigarette smoking and the incidence of breast cancer. Arch Intern Med 171(2):125–133PubMedCrossRef
Metadata
Title
The risk of a second primary lung cancer after a first invasive breast cancer according to estrogen receptor status
Authors
Sara J. Schonfeld
Rochelle E. Curtis
William F. Anderson
Amy Berrington de González
Publication date
01-10-2012
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 10/2012
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-012-0054-3

Other articles of this Issue 10/2012

Cancer Causes & Control 10/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine